GlassScriptPhysician profile
Daniel P Owens
NPI 1750544250
$342,737.44
in general payments reported to CMS, 2019-2025
14 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $17.12 · 2021: $631 · 2022: $158K · 2023: $183K · 2024: $258 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $183K · Food and Beverage: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $183,082.68 |
| Food and Beverage | $507.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $341,237.68 | 2022-2023 | Hillrom - Retinavue 700 Imager, Hillrom - Retinavue Network |
| Abbvie INC. | $612.26 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $229.63 | 2023 | Eylea Hd, Eylea |
| Allergan, INC. | $156.92 | 2019-2021 | |
| Welch Allyn | $150.00 | 2019 | |
| Cardinal Health 110 LLC | $150.00 | 2024 | |
| Alcon Vision LLC | $42.85 | 2025 | Unity |
| Sight Sciences, INC. | $35.56 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Astellas Pharma US INC | $32.01 | 2025 | Izervay |
| Amgen INC. | $24.38 | 2025 | Tepezza |
| Apellis Pharmaceuticals, INC. | $20.54 | 2023 | |
| Novartis Pharmaceuticals Corporation | $17.12 | 2020 | |
| Boston Scientific Corporation | $15.11 | 2023 | Advantage System |
| Integra Lifesciences Corporation | $13.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Owens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.